STAT+：尽管诺和诺德的药物失败，心脏病专家表示他们仍将致力于抗炎药物
摘要
芝加哥——失控的炎症常被称为心血管和代谢疾病的万恶之源。7月简要描述的近期临床试验结果显示，尽管一种实验性药物能够降低两种炎症生物标志物，但并未减少重症患者的严重心脏事件。这项名为ZEUS的诺和诺德研究显示，单克隆抗体ziltivekimab降低了炎症细胞因子白细胞介素-6（IL-6）的水平，但与安慰剂组相比，治疗组的这一下降并未转化为更少的心脏病发作、中风或死亡。在公布主要结果后，诺和诺德停止了该药物的另外两项试验HERMES和ATHENA，此前数据监测委员会在9月发现它们不太可能达
English
CHICAGO — Out-of-control inflammation is often called the root of all evil in cardiovascular and metabolic disease. Recent clinical trial results, described in brief in July , showed that while an experimental drug could lower two biomarkers of inflammation, it didn’t limit serious heart events in patients with severe illness. The Novo Nordisk study, called ZEUS, showed that the monoclonal antibody ziltivekimab reduced levels of the inflammatory cytokine interleukin-6, or IL-6, but that drop did not translate into fewer heart attacks, strokes, or deaths in the treatment group compared to those taking a placebo. Once top-line results were disclosed, Novo halted two other trials of the drug called HERMES and ATHENA after a data monitoring committee found in September they were unlikely to su